HighTower Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

HighTower Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,058	Closed	-$788K	–	3988
2026 Q1	$788K	Buy	+9,058	New	+$881K	﹤0.01%	2364
2021 Q2	–	Sell	-24,053	Closed	-$512K	–	3354
2021 Q1	$512K	Sell	24,053 -2,050	-8%	-$59.5K	﹤0.01%	1952
2020 Q4	$776K	Buy	+26,103	New	+$663K	﹤0.01%	1401

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HighTower Advisors's RYTM Position: Q2 2026 in Review

HighTower Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 9,058 shares — an estimated $788K sold.

HighTower Advisors first reported a position in RYTM in Q4 2020 and held it in 3 quarters. The position peaked at $788K in Q1 2026. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

HighTower Advisors reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HighTower Advisors sold 9,058 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $788K.
HighTower Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2020 and held it in 3 quarters.
HighTower Advisors's Rhythm Pharmaceuticals position peaked at $788K in Q1 2026.
302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.